Payment overview · 2025
General Payments
$221.86
13 reported records · 8 companies
Healthcare provider profile · identity verified
Shane Mcdougal, MD
Allopathic & Osteopathic Physicians|Family Medicine · WHITESBURG, KY · NPI 1104871862
Verified facts
What the public records show
CMS Open Payments records show Shane Mcdougal, MD received $221.86 in general payments during 2025 across 13 reported records.
Exact Sciences Corporation accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.69 | 20.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.02 | 19.8% | 3 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $38.20 | 17.2% | 2 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $31.77 | 14.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.27 | 8.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.25 | 6.9% | 1 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $15.00 | 6.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.66 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $190.09 | 11 |
| Education | $31.77 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.69 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.02 | 3 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.42 | 2 | 2025 |
Source payment records
|
|||||
| XACDURO Normalized: xacduro |
Drug | La Jolla Pharmaceutical Company | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| ZEVTERA Normalized: zevtera |
Drug | La Jolla Pharmaceutical Company | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 505 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 433 | 110 |
| Omeprazole | Omeprazole | 432 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 415 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 391 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 77 |
| Gabapentin | Gabapentin | 321 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 295 | 77 |
| Losartan Potassium | Losartan Potassium | 262 | 71 |
| Metformin Hcl | Metformin Hcl | 252 | 63 |
| Sertraline Hcl | Sertraline Hcl | 243 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 197 | 55 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 194 | 43 |
| Famotidine | Famotidine | 171 | 41 |
| Potassium Chloride | Potassium Chloride | 159 | 45 |
| Montelukast Sodium | Montelukast Sodium | 146 | 40 |
| Cefdinir | Cefdinir | 132 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 129 | 32 |
| Eliquis | Apixaban | 128 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 31 |
| Valsartan | Valsartan | 114 | 33 |
| Meloxicam | Meloxicam | 112 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 32 |
| Carvedilol | Carvedilol | 109 | 24 |
| Farxiga | Dapagliflozin Propanediol | 106 | 29 |
| Tramadol Hcl | Tramadol Hcl | 105 | 20 |
| Finasteride | Finasteride | 102 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 33 |
| Prednisone | Prednisone | 93 | 79 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 91 | 24 |
| Furosemide | Furosemide | 86 | 34 |
| Donepezil Hcl | Donepezil Hcl | 80 | 19 |
| Ozempic | Semaglutide | 79 | 17 |
| Nifedipine Er | Nifedipine | 75 | 21 |
| Ibuprofen | Ibuprofen | 70 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 53 |
| Methocarbamol | Methocarbamol | 63 | 19 |
| Pregabalin | Pregabalin | 59 | 13 |
| Bumetanide | Bumetanide | 57 | 13 |
| Simvastatin | Simvastatin | 57 | 13 |
| Allopurinol | Allopurinol | 53 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Atenolol | Atenolol | 44 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 12 |
| Telmisartan | Telmisartan | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 13 |
| Glimepiride | Glimepiride | 37 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 11 |
| Topiramate | Topiramate | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 15 |
| Spironolactone | Spironolactone | 35 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 17 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 20 |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Primidone | Primidone | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.86 · 13 records | Exact Sciences Corporation | Cologuard Collection Kit, EVENITY, Kimyrsa, MOUNJARO, PONVORY, RAYALDEE, Wegovy, XACDURO, ZEPBOUND, ZEVTERA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error